The Human Immune Monitoring Center (HIMC) provides state-of-the-art assays that measure biomarkers relevant to the immune system or specific pathogens. Examples of biomarkers that are specifically relevant to cancer include changes in lymphocyte signaling pathways, serum cytokines and specific immune responses that target tumor cells. This shared resource offers SCI members specialized assays that monitor the effects and efficacy of immunotherapies and vaccination strategies that are becoming increasingly important alternatives or adjuvants to conventional cancer treatment. In addition, pathogens have been implicated in the etiology of many cancers, and the HIMC offers an array of methodologies for pathogen identification. The HIMC initiated operations in 2007 and has attracted many faculty users in the past six years. We expect an increasing demand for the services of HIMC as new recruitments, projects and clinical trials related to the immune modulation of cancer are developed by the SCI. The HIMC offers standardized assays to analyze secreted cytokines (using Luminex and MesoScale Discovery platforms), cell subsets and functions (by flow cytometry and CyTOF) and gene expression (by microarray, qPCR, and targeted RNAseq). It also provides sample processing and biobanking services, and it maintains an integrated, online database of assay results and clinical/demographic data with a total operating budget of $2M. Since 2009, over 55 SCI members have used the shared resource, representing all program affiliations. Dr. Holden Maecker is the Facility Director and an expert in cancer immunology and immune monitoring. Oversight is provided by the HIMC Advisory Committee, headed by Dr. Mark Davis, SCI member and an internationally renowned expert in lymphocyte recognition and immune monitoring technologies. Future goals of the HIMC are to introduce a standardized targeted RNAseq panel for gene expression and T cell receptor sequencing of single-sorted T cells. In addition, single cell tissue (e.g., tumor biopsy) isolation, processing and cryopreservation will be developed as well as online access to the BioBank inventory for investigators to quickly create queries and reports.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA124435-10
Application #
9308885
Study Section
Special Emphasis Panel (ZCA1-RTRB-0)
Project Start
Project End
Budget Start
2017-06-01
Budget End
2018-05-31
Support Year
10
Fiscal Year
2017
Total Cost
$52,807
Indirect Cost
$19,388
Name
Stanford University
Department
Type
Domestic Higher Education
DUNS #
009214214
City
Stanford
State
CA
Country
United States
Zip Code
94304
Pollom, Erqi L; Fujimoto, Dylann K; Han, Summer S et al. (2018) Newly diagnosed glioblastoma: adverse socioeconomic factors correlate with delay in radiotherapy initiation and worse overall survival. J Radiat Res 59:i11-i18
Nørgaard, Caroline Holm; Jakobsen, Lasse Hjort; Gentles, Andrew J et al. (2018) Subtype assignment of CLL based on B-cell subset associated gene signatures from normal bone marrow - A proof of concept study. PLoS One 13:e0193249
Im, Hogune; Rao, Varsha; Sridhar, Kunju et al. (2018) Distinct transcriptomic and exomic abnormalities within myelodysplastic syndrome marrow cells. Leuk Lymphoma 59:2952-2962
Huang, Min; Zhu, Li; Garcia, Jacqueline S et al. (2018) Brd4 regulates the expression of essential autophagy genes and Keap1 in AML cells. Oncotarget 9:11665-11676
Chiou, Shin-Heng; Dorsch, Madeleine; Kusch, Eva et al. (2018) Hmga2 is dispensable for pancreatic cancer development, metastasis, and therapy resistance. Sci Rep 8:14008
Breslow, David K; Hoogendoorn, Sascha; Kopp, Adam R et al. (2018) A CRISPR-based screen for Hedgehog signaling provides insights into ciliary function and ciliopathies. Nat Genet 50:460-471
Chu, Lisa W; Till, Cathee; Yang, Baiyu et al. (2018) Circadian genes and risk of prostate cancer in the prostate cancer prevention trial. Mol Carcinog 57:462-466
Patel, Manali I; Sundaram, Vandana; Desai, Manisha et al. (2018) Effect of a Lay Health Worker Intervention on Goals-of-Care Documentation and on Health Care Use, Costs, and Satisfaction Among Patients With Cancer: A Randomized Clinical Trial. JAMA Oncol 4:1359-1366
Trieu, Vanessa; Pinto, Harlan; Riess, Jonathan W et al. (2018) Weekly Docetaxel, Cisplatin, and Cetuximab in Palliative Treatment of Patients with Squamous Cell Carcinoma of the Head and Neck. Oncologist 23:764-e86
Kuonen, François; Surbeck, Isabelle; Sarin, Kavita Y et al. (2018) TGF?, Fibronectin and Integrin ?5?1 Promote Invasion in Basal Cell Carcinoma. J Invest Dermatol 138:2432-2442

Showing the most recent 10 out of 322 publications